PRNewsWire
02 Apr 2026, 14:00 UTC · 30w ago
Impact · against what's priced in
Immutep faces severe valuation headwinds following a Phase III trial failure and a subsequent 82% price crash, now compounded by a securities fraud investigation. Primoris and Megan Holdings are facing separate class action lawsuits, introducing additional legal and financial risk.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish
The TACTI-004 Phase III study for eftilagimod alfa in non-small cell lung cancer has been discontinued for futility.
More negative than 99% of claims this week
Immutep's ADR price plummeted 82.44% to $0.48 following the announcement of the trial's discontinuation.
So whatExtreme price volatility and a massive loss in market capitalization indicate a severe loss of investor confidence in the company's valuation.
Continue reading
5 related stories
The discontinuation of the TACTI-004 Phase III study for futility led to an 82.44% price crash, and the subsequent investigation into securities fraud adds further legal liability.
Read from the article alone
No priced-in read yet
The company is now the subject of a class action lawsuit filed by Pomerantz LLP.
Read from the article alone
No priced-in read yet
The company is facing a class action lawsuit regarding investor losses.
Read from the article alone
Scored by the NIS engine · methodology.
Search tags
More negative than 94% of claims this week
Pomerantz LLP is investigating Immutep for potential securities fraud or unlawful business practices related to the trial failure.
More negative than 86% of claims this week
Which stocks this story touches
More negative than 99% of ticker scores this week
The company is facing a securities fraud investigation following the discontinuation of a Phase III clinical trial for futility and a subsequent 82% stock price crash.
More negative than 92% of ticker scores this week
The company is the subject of a class action lawsuit.
More negative than 92% of ticker scores this week
The company is the subject of a class action lawsuit regarding investor losses.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
3h ago
−23.4%
Price agrees with the score
$3.57 vs $4.66 close before publication (Apr 1) · not market-adjusted
MGN chart →−59.5%
Price agrees with the score
$3.00 vs $7.40 close before publication (Apr 1) · not market-adjusted
IMMP chart →−47.1%
Price agrees with the score
$79.63 vs $150.67 close before publication (Apr 1) · not market-adjusted
PRIM chart →
